Jane Street
LYEL icon

Jane Street’s Lyell Immunopharma LYEL Stock Holding History

Jane Street’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-505
Closed -$35K – 9543
2022
Q4 		$35K Buy
+505
New +$50.2K ﹤0.01% 8467

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Jane Street's LYEL Position: Q2 2026 in Review

Jane Street reduced its Lyell Immunopharma (LYEL) stake by 28% in Q2 2026, selling an estimated $324K and leaving 46,011 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #7450.

Jane Street first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.28M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Jane Street held 46,011 shares of Lyell Immunopharma worth $646K as of Q2 2026.
  • Jane Street sold 17,882 Lyell Immunopharma shares in Q2 2026, an estimated $324K.
  • Lyell Immunopharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7450 holding.
  • Jane Street first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • Jane Street's Lyell Immunopharma position peaked at $1.28M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.